People_

Associate Professor Venessa Hin Man Tsang

Associate Professor- Medicine, Northern Clinical SchoolSenior Staff Specialist in Endocrinology- Royal North Shore Hospital

Phone

+61 2 9463 1680

Fax

+61 2 9463 1045

Email

venessa.tsang@sydney.edu.au

Biographical details

Associate Professor Venessa Tsang was appointed to the Sydney Medical School, Northern, in 2014 and has been a Senior Staff Specialist in Endocrinology at Royal North Shore Hospital since 2012. She completed her undergraduate medical degree at the University of New South Wales in 2003, and trained as an Endocrinologist at Royal North Shore Hospital and St Vincent’s Hospital Sydney, gaining her fellowship in 2010. She continues to practise clinical endocrinology at Sydney’s Royal North Shore Hospital as a Staff Specialist.

Research interests

Immune related adverse effects of immune checkpoint inhibitor therapy.

Endocrine cancers including advanced thyroid cancer, phaeochromocytomas, paragangliomas.

Type 3c diabetes post pancreatic surgery

Medical education

Teaching and supervision

Endocrinology

Themes

Cancer

Keywords

Cancer, Endocrinology, Genetics, Medical education, Molecular biology

Approaches

Cellular/Molecular, Education, Genetics

Publications

By Type

Expand all

Book Chapters

Tsang, V., Tacon, L., Learoyd, D., Robinson, B. (2015). Pheochromocytomas in Multiple Endocrine Neoplasia Type 2. In Friedhelm Raue (Eds.), Medullary Thyroid Carcinoma: Biology - Management - Treatment, (pp. 157-178). Cham: Springer. [More Information]

Journals

Wu, L., Tsang, V., Gunton, J., Carlino, M., Brown, D., Long, G., Clifton-Bligh, R., Mellor, R., Moore, K., Sasson, S., Menzies, A. (2024). Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy. Journal of Clinical Endocrinology and Metabolism, 109(5), 1301-1307. [More Information]
Aksoy, Y., Chou, A., Clarkson, A., Clifton-Bligh, R., De Leo, A., Dogan, S., Ganly, I., Ghossein, R., Gild, M., Glover, A., Papachristos, A., Robinson, B., Sidhu, S., Sywak, M., Tsang, V., Turchini, J., Gill, A., Fuchs, T., Seyed Ahadi, M., et al (2024). Novel prognostic nomogram for predicting recurrence-free survival in medullary thyroid carcinoma. Histopathology, 84(6), 947-959. [More Information]
Davidoff, D., De Abreu Lourenco, R., Tsang, V., Benn, D., Clifton-Bligh, R. (2024). Outcomes of SDHB Pathogenic Variant Carriers. Journal of Clinical Endocrinology and Metabolism, 109(9), 2400-2410. [More Information]
Gild, M., Schembri, G., Clifton-Bligh, R., Hoang, J., Kumar, S., Fuchs, T., Glover, A., Sidhu, S., Sywak, M., Tsang, V., Gill, A., Robinson, B. (2024). The Clinical Utility of Gallium-68-DOTATATE Positron Emission Tomography Scanning in Medullary Thyroid Cancer. Endocrine Practice. [More Information]
Li, M., Chan, D., Tapia Rico, G., Cehic, G., Lawrence, B., Wyld, D., Pattison, D., Kong, G., Hicks, R., Michael, M., Clifton-Bligh, R., Tsang, V., Roach, P., Diakos, C., Pavlakis, N., et al (2023). Australasian Consensus Statement on the Identification, Prevention, and Management of Hormonal Crises in Patients with Neuroendocrine Neoplasms Undergoing Peptide Receptor Radionuclide Therapy. Neuroendocrinology, 113(3), 281-288. [More Information]
Gild, M., Bullock, M., Tsang, V., Clifton-Bligh, R., Robinson, B., Wirth, L. (2023). Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics. Thyroid, 33(6), 682-690. [More Information]
Worrall, B., Papachristos, A., Aniss, A., Glover, A., Sidhu, S., Clifton-Bligh, R., Learoyd, D., Tsang, V., Gild, M., Robinson, B., Sywak, M. (2023). Lobectomy and completion thyroidectomy rates increase after the 2015 American Thyroid Association Differentiated Thyroid Cancer Guidelines update. Endocrine Oncology, 3(1), e220095. [More Information]
Kesby, N., Mechera, R., Fuchs, T., Papachristos, A., Gild, M., Tsang, V., Clifton-Bligh, R., Robinson, B., Sywak, M., Sidhu, S., Chou, A., Gill, A., Glover, A. (2023). Natural History and Predictive Factors of Outcome in Medullary Thyroid Microcarcinoma. Journal of Clinical Endocrinology and Metabolism, 108(10), 2626-2634. [More Information]
Wu, L., Tsang, V., Menzies, A., Sasson, S., Carlino, M., Brown, D., Clifton-Bligh, R., Gunton, J. (2023). Risk Factors and Characteristics of Checkpoint Inhibitor– Associated Autoimmune Diabetes Mellitus (CIADM): A Systematic Review and Delineation From Type 1 Diabetes. Diabetes Care, 46(6), 1292-1299. [More Information]
Muir, C., Wood, C., Clifton-Bligh, R., Long, G., Scolyer, R., Carlino, M., Menzies, A., Tsang, V. (2022). Association of Antithyroid Antibodies in Checkpoint Inhibitor-Associated Thyroid Immune-Related Adverse Events. Journal of Clinical Endocrinology and Metabolism, 107(5), e1843-e1849. [More Information]
Percy, K., Ooi, Y., Nahm, C., Simpson, F., Hickey, G., Sahni, S., Chesher, D., Itchins, M., Pavlakis, N., Tsang, V., Clifton-Bligh, R., Gill, A., Mittal, A., et al (2022). Defining the rate of nutritional and metabolic derangements after pancreatic resection. Pancreatology, 22(7), 1028-1034. [More Information]
Muir, C., Tsang, V., Menzies, A., Clifton-Bligh, R. (2022). Immune Related Adverse Events of the Thyroid – A Narrative Review. Frontiers in Endocrinology, 13. [More Information]
Papachristos, A., Do, K., Tsang, V., Sywak, M., Gill, A., Sidhu, S., Clifton-Bligh, R., Glover, A., Gild, M. (2022). Outcomes of Papillary Thyroid Microcarcinoma Presenting with Palpable Lateral Lymphadenopathy. Thyroid, 32(9), 1086-1093. [More Information]
Tsang, V., Gill, A., Gild, M., Lurie, B., Blumer, L., Siddall, R., Clifton-Bligh, R., Robinson, B. (2022). Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects. Journal of Clinical Endocrinology and Metabolism, 107(9), E3824-E3829. [More Information]
Gild, M., Tsang, V., Clifton-Bligh, R., Robinson, B. (2021). Multikinase inhibitors in thyroid cancer: timing of targeted therapy. Nature Reviews Endocrinology, 17(4), 225-234. [More Information]
Jonker, P., Turchini, J., Kruijff, S., Lin, J., Gill, A., Eade, T., Aniss, A., Clifton-Bligh, R., Learoyd, D., Robinson, B., Tsang, V., Glover, A., Sidhu, S., Sywak, M. (2021). Multimodality Treatment Improves Locoregional Control, Progression-Free and Overall Survival in Patients with Anaplastic Thyroid Cancer: A Retrospective Cohort Study Comparing Oncological Outcomes and Morbidity between Multimodality Treatment and Limited Treatment. Annals of Surgical Oncology, 28(12), 7520-7530. [More Information]
Sutherland, R., Tsang, V., Clifton-Bligh, R., Gild, M. (2021). Papillary thyroid microcarcinoma: Is active surveillance always enough? Clinical Endocrinology, 95(6), 811-817. [More Information]
Jaffar, S., Jayasekara, J., Aniss, A., Tsang, V., Learoyd, D., Clifton-Bligh, R., Gill, A., Glover, A., Sidhu, S., Robinson, B., Sywak, M. (2021). Predicting distant metastatic disease in differentiated thyroid cancer: a matched case-control study. ANZ Journal of Surgery, 91(4), 716-723. [More Information]
Muir, C., Clifton-Bligh, R., Long, G., Scolyer, R., Lo, S., Carlino, M., Tsang, V., Menzies, A. (2021). Thyroid Immune-related Adverse Events following Immune Checkpoint Inhibitor Treatment. Journal of Clinical Endocrinology and Metabolism, 106(9), E3704-E3713. [More Information]
Wu, L., Tsang, V., Sasson, S., Menzies, A., Carlino, M., Brown, D., Clifton-Bligh, R., Gunton, J. (2021). Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside. Frontiers in Endocrinology, 12, 764138. [More Information]
Fuchs, T., Nassour, A., Glover, A., Sywak, M., Sidhu, S., Delbridge, L., Clifton-Bligh, R., Gild, M., Tsang, V., Robinson, B., Cho, A., Gill, A., et al (2020). A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis. American Journal of Surgical Pathology, 44(10), 1419-1428. [More Information]
Lin, M., Tsang, V., Brewer, J., Clifton-Bligh, R., Gild, M. (2020). Infiltrative lymphocytic hypophysitis successfully treated with rituximab and mycophenolate mofetil. Endocrinology, Diabetes & Metabolism Case Reports, 2020 (1), 1-6. [More Information]
Nylen, C., Mechera, R., Marechal-Ross, I., Tsang, V., Chou, A., Gill, A., Clifton-Bligh, R., Robinson, B., Sywak, M., Sidhu, S., Glover, A. (2020). Molecular Markers Guiding Thyroid Cancer Management. Cancers, 12(8), 1-26. [More Information]
Tsang, V., McGrath, R., Clifton-Bligh, R., Scolyer, R., Jakrot, V., Guminski, A., Long, G., Menzies, A. (2020). Response to letter to the editor: "checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes-inhibitor-associated. Journal of Clinical Endocrinology and Metabolism, 105(6), dgaa144. [More Information]
Wu, L., Nahm, C., Jamieson, N., Samra, J., Clifton-Bligh, R., Mittal, A., Tsang, V. (2020). Risk factors for development of diabetes mellitus (Type 3c) after partial pancreatectomy: A systematic review. Clinical Endocrinology, 92(5), 396-406. [More Information]
Tsang, V., Gild, M., Glover, A., Clifton-Bligh, R., Robinson, B. (2020). Thyroid cancer in the age of COVID-19. Endocrine-Related Cancer, 27(11), R407-R416. [More Information]
Muir, C., Menzies, A., Clifton-Bligh, R., Tsang, V. (2020). Thyroid Toxicity following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. Thyroid, 30(10), 1458-1469. [More Information]
Tsang, V., McGrath, R., Clifton-Bligh, R., Scolyer, R., Jakrot, V., Guminski, A., Long, G., Menzies, A. (2019). Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 104(11), 5499-5506. [More Information]
Tsang, V. (2019). Management of treatment-related toxicities in advanced medullary thyroid cancer. Current Opinion in Oncology, 31(3), 236-242. [More Information]
Wijetunga, A., Tsang, V., Giuffre, B. (2019). The utility of cross-sectional imaging in the management of suspected scaphoid fractures. Journal of Medical Radiation Sciences, 66(1), 30-37. [More Information]
De Sousa, S., Sheriff, N., Tran, C., Menzies, A., Tsang, V., Long, G., Tonks, K. (2018). Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. Pituitary, 21(3), 274-282. [More Information]
Gild, M., Tsang, V., Samra, J., Clifton-Bligh, R., Tacon, L., Gill, A. (2018). Hypercalcemia in glucagon cell hyperplasia and neoplasia (Mahvash syndrome): a new association. Journal of Clinical Endocrinology and Metabolism, 103(9), 3119-3123. [More Information]
Jang, H., Parratt, J., Tsang, V., Coyle, L., Fernando, S. (2018). Serum vascular endothelial growth factor (VEGF) level can be used as a diagnostic marker in POEMS syndrome. Pathology, 50(6), 674-676. [More Information]
Scott, E., Long, G., Guminski, A., Clifton-Bligh, R., Menzies, A., Tsang, V. (2018). The Spectrum, Incidence, Kinetics, and Management of Endocrinopathies with Immune Checkpoint Inhibitors for Metastatic Melanoma. European Journal of Endocrinology, 178(2), 175-182. [More Information]
Wijewardene, A., Glastras, S., Learoyd, D., Robinson, B., Tsang, V. (2017). ACTH-secreting medullary thyroid cancer: a case series. Endocrinology, Diabetes & Metabolism Case Reports, 2017, 1-6. [More Information]
Kam, J., Tsang, V., Chalasani, V. (2017). Retrograde Ejaculation: A Rare Presenting Symptom of Type 1 Diabetes Mellitus. Urology Case Reports, 10, 9-10. [More Information]
Logaraj, A., Tsang, V., Kabir, S., Ip, J. (2016). Adrenal crisis secondary to bilateral adrenal haemorrhage after hemicolectomy. Endocrinology, Diabetes & Metabolism Case Reports, 2016, 1-4. [More Information]
Fraser, S., Go, C., Aniss, A., Sidhu, S., Delbridge, L., Learoyd, D., Clifton-Bligh, R., Tacon, L., Tsang, V., Robinson, B., Gill, A., Sywak, M. (2016). BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer. World Journal of Surgery, 40(7), 1618-1624. [More Information]
Tsang, V., Robinson, B., Learoyd, D. (2016). The safety of vandetanib for the treatment of thyroid cancer. Expert Opinion on Drug Safety, 15(8), 1107-1113. [More Information]
Kozusko, K., Tsang, V., Bottomley, W., Cho, Y., Gandotra, S., Mimmack, M., Lim, K., Isaac, I., Patel, S., Saudek, V., et al (2015). Clinical and molecular characterization of a novel PLIN1 frameshift mutation identified in patients with familial partial lipodystrophy. Diabetes, 64(1), 299-310. [More Information]
Kim, E., Rath, E., Tsang, V., Duff, A., Robinson, B., Church, W., Benn, D., Dwight, T., Clifton-Bligh, R. (2015). Structural and functional consequences of succinate dehydrogenase subunit B mutations. Endocrine-Related Cancer, 22(3), 387-397. [More Information]
Tsang, V., Dwight, T., Benn, D., Meyer-Rochow, G., Gill, A., Sywak, M., Sidhu, S., Veivers, D., Sue, C., Robinson, B., Clifton-Bligh, R., Parker, N. (2014). Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours. Endocrine-Related Cancer, 21(3), 415-426. [More Information]
Tsang, V., Campbell, L. (2010). Catecho-Strophic Diabetic Ketoacidosis. The Best of Grand Rounds Wiley-Blackwell Publishing Award for Clinical Excellence. Internal Medicine Journal, 40(Suppl. 1), 58-58. [More Information]

show 40 more

Conferences

Tsang, V., Parker, N., Cassano, J., Dwight, T., Sue, C., Veivers, D., Robinson, B., Benn, D., Clifton-Bligh, R. (2012). Interaction between hypoxia and mutations in the SDH subunit genes associated with phaeochromocytoma/paragangliomas. 2012 Annual Scientific Meeting of the Endocrine Society of Australia and the Society for Reproductive Biology, Gold Coast, Queensland, Australia.
Tsang, V., Benn, D., Gill, A., Sywak, M., Sidhu, S., Robinson, B., Clifton-Bligh, R., Parker, N. (2011). MiR210 is elevated in SDHB-mutated phaeochromocytoma and paragangliomas (poster). 3rd International Symposium on Pheochromocytoma and Paraganglioma, Paris, France.

By Year

Expand all

2024

Wu, L., Tsang, V., Gunton, J., Carlino, M., Brown, D., Long, G., Clifton-Bligh, R., Mellor, R., Moore, K., Sasson, S., Menzies, A. (2024). Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy. Journal of Clinical Endocrinology and Metabolism, 109(5), 1301-1307. [More Information]
Aksoy, Y., Chou, A., Clarkson, A., Clifton-Bligh, R., De Leo, A., Dogan, S., Ganly, I., Ghossein, R., Gild, M., Glover, A., Papachristos, A., Robinson, B., Sidhu, S., Sywak, M., Tsang, V., Turchini, J., Gill, A., Fuchs, T., Seyed Ahadi, M., et al (2024). Novel prognostic nomogram for predicting recurrence-free survival in medullary thyroid carcinoma. Histopathology, 84(6), 947-959. [More Information]
Davidoff, D., De Abreu Lourenco, R., Tsang, V., Benn, D., Clifton-Bligh, R. (2024). Outcomes of SDHB Pathogenic Variant Carriers. Journal of Clinical Endocrinology and Metabolism, 109(9), 2400-2410. [More Information]
Gild, M., Schembri, G., Clifton-Bligh, R., Hoang, J., Kumar, S., Fuchs, T., Glover, A., Sidhu, S., Sywak, M., Tsang, V., Gill, A., Robinson, B. (2024). The Clinical Utility of Gallium-68-DOTATATE Positron Emission Tomography Scanning in Medullary Thyroid Cancer. Endocrine Practice. [More Information]

show 1 more

2023

Li, M., Chan, D., Tapia Rico, G., Cehic, G., Lawrence, B., Wyld, D., Pattison, D., Kong, G., Hicks, R., Michael, M., Clifton-Bligh, R., Tsang, V., Roach, P., Diakos, C., Pavlakis, N., et al (2023). Australasian Consensus Statement on the Identification, Prevention, and Management of Hormonal Crises in Patients with Neuroendocrine Neoplasms Undergoing Peptide Receptor Radionuclide Therapy. Neuroendocrinology, 113(3), 281-288. [More Information]
Gild, M., Bullock, M., Tsang, V., Clifton-Bligh, R., Robinson, B., Wirth, L. (2023). Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics. Thyroid, 33(6), 682-690. [More Information]
Worrall, B., Papachristos, A., Aniss, A., Glover, A., Sidhu, S., Clifton-Bligh, R., Learoyd, D., Tsang, V., Gild, M., Robinson, B., Sywak, M. (2023). Lobectomy and completion thyroidectomy rates increase after the 2015 American Thyroid Association Differentiated Thyroid Cancer Guidelines update. Endocrine Oncology, 3(1), e220095. [More Information]
Kesby, N., Mechera, R., Fuchs, T., Papachristos, A., Gild, M., Tsang, V., Clifton-Bligh, R., Robinson, B., Sywak, M., Sidhu, S., Chou, A., Gill, A., Glover, A. (2023). Natural History and Predictive Factors of Outcome in Medullary Thyroid Microcarcinoma. Journal of Clinical Endocrinology and Metabolism, 108(10), 2626-2634. [More Information]
Wu, L., Tsang, V., Menzies, A., Sasson, S., Carlino, M., Brown, D., Clifton-Bligh, R., Gunton, J. (2023). Risk Factors and Characteristics of Checkpoint Inhibitor– Associated Autoimmune Diabetes Mellitus (CIADM): A Systematic Review and Delineation From Type 1 Diabetes. Diabetes Care, 46(6), 1292-1299. [More Information]

show 2 more

2022

Muir, C., Wood, C., Clifton-Bligh, R., Long, G., Scolyer, R., Carlino, M., Menzies, A., Tsang, V. (2022). Association of Antithyroid Antibodies in Checkpoint Inhibitor-Associated Thyroid Immune-Related Adverse Events. Journal of Clinical Endocrinology and Metabolism, 107(5), e1843-e1849. [More Information]
Percy, K., Ooi, Y., Nahm, C., Simpson, F., Hickey, G., Sahni, S., Chesher, D., Itchins, M., Pavlakis, N., Tsang, V., Clifton-Bligh, R., Gill, A., Mittal, A., et al (2022). Defining the rate of nutritional and metabolic derangements after pancreatic resection. Pancreatology, 22(7), 1028-1034. [More Information]
Muir, C., Tsang, V., Menzies, A., Clifton-Bligh, R. (2022). Immune Related Adverse Events of the Thyroid – A Narrative Review. Frontiers in Endocrinology, 13. [More Information]
Papachristos, A., Do, K., Tsang, V., Sywak, M., Gill, A., Sidhu, S., Clifton-Bligh, R., Glover, A., Gild, M. (2022). Outcomes of Papillary Thyroid Microcarcinoma Presenting with Palpable Lateral Lymphadenopathy. Thyroid, 32(9), 1086-1093. [More Information]
Tsang, V., Gill, A., Gild, M., Lurie, B., Blumer, L., Siddall, R., Clifton-Bligh, R., Robinson, B. (2022). Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects. Journal of Clinical Endocrinology and Metabolism, 107(9), E3824-E3829. [More Information]

show 2 more

2021

Gild, M., Tsang, V., Clifton-Bligh, R., Robinson, B. (2021). Multikinase inhibitors in thyroid cancer: timing of targeted therapy. Nature Reviews Endocrinology, 17(4), 225-234. [More Information]
Jonker, P., Turchini, J., Kruijff, S., Lin, J., Gill, A., Eade, T., Aniss, A., Clifton-Bligh, R., Learoyd, D., Robinson, B., Tsang, V., Glover, A., Sidhu, S., Sywak, M. (2021). Multimodality Treatment Improves Locoregional Control, Progression-Free and Overall Survival in Patients with Anaplastic Thyroid Cancer: A Retrospective Cohort Study Comparing Oncological Outcomes and Morbidity between Multimodality Treatment and Limited Treatment. Annals of Surgical Oncology, 28(12), 7520-7530. [More Information]
Sutherland, R., Tsang, V., Clifton-Bligh, R., Gild, M. (2021). Papillary thyroid microcarcinoma: Is active surveillance always enough? Clinical Endocrinology, 95(6), 811-817. [More Information]
Jaffar, S., Jayasekara, J., Aniss, A., Tsang, V., Learoyd, D., Clifton-Bligh, R., Gill, A., Glover, A., Sidhu, S., Robinson, B., Sywak, M. (2021). Predicting distant metastatic disease in differentiated thyroid cancer: a matched case-control study. ANZ Journal of Surgery, 91(4), 716-723. [More Information]
Muir, C., Clifton-Bligh, R., Long, G., Scolyer, R., Lo, S., Carlino, M., Tsang, V., Menzies, A. (2021). Thyroid Immune-related Adverse Events following Immune Checkpoint Inhibitor Treatment. Journal of Clinical Endocrinology and Metabolism, 106(9), E3704-E3713. [More Information]
Wu, L., Tsang, V., Sasson, S., Menzies, A., Carlino, M., Brown, D., Clifton-Bligh, R., Gunton, J. (2021). Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside. Frontiers in Endocrinology, 12, 764138. [More Information]

show 3 more

2020

Fuchs, T., Nassour, A., Glover, A., Sywak, M., Sidhu, S., Delbridge, L., Clifton-Bligh, R., Gild, M., Tsang, V., Robinson, B., Cho, A., Gill, A., et al (2020). A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis. American Journal of Surgical Pathology, 44(10), 1419-1428. [More Information]
Lin, M., Tsang, V., Brewer, J., Clifton-Bligh, R., Gild, M. (2020). Infiltrative lymphocytic hypophysitis successfully treated with rituximab and mycophenolate mofetil. Endocrinology, Diabetes & Metabolism Case Reports, 2020 (1), 1-6. [More Information]
Nylen, C., Mechera, R., Marechal-Ross, I., Tsang, V., Chou, A., Gill, A., Clifton-Bligh, R., Robinson, B., Sywak, M., Sidhu, S., Glover, A. (2020). Molecular Markers Guiding Thyroid Cancer Management. Cancers, 12(8), 1-26. [More Information]
Tsang, V., McGrath, R., Clifton-Bligh, R., Scolyer, R., Jakrot, V., Guminski, A., Long, G., Menzies, A. (2020). Response to letter to the editor: "checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes-inhibitor-associated. Journal of Clinical Endocrinology and Metabolism, 105(6), dgaa144. [More Information]
Wu, L., Nahm, C., Jamieson, N., Samra, J., Clifton-Bligh, R., Mittal, A., Tsang, V. (2020). Risk factors for development of diabetes mellitus (Type 3c) after partial pancreatectomy: A systematic review. Clinical Endocrinology, 92(5), 396-406. [More Information]
Tsang, V., Gild, M., Glover, A., Clifton-Bligh, R., Robinson, B. (2020). Thyroid cancer in the age of COVID-19. Endocrine-Related Cancer, 27(11), R407-R416. [More Information]
Muir, C., Menzies, A., Clifton-Bligh, R., Tsang, V. (2020). Thyroid Toxicity following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. Thyroid, 30(10), 1458-1469. [More Information]

show 4 more

2019

Tsang, V., McGrath, R., Clifton-Bligh, R., Scolyer, R., Jakrot, V., Guminski, A., Long, G., Menzies, A. (2019). Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 104(11), 5499-5506. [More Information]
Tsang, V. (2019). Management of treatment-related toxicities in advanced medullary thyroid cancer. Current Opinion in Oncology, 31(3), 236-242. [More Information]
Wijetunga, A., Tsang, V., Giuffre, B. (2019). The utility of cross-sectional imaging in the management of suspected scaphoid fractures. Journal of Medical Radiation Sciences, 66(1), 30-37. [More Information]

2018

De Sousa, S., Sheriff, N., Tran, C., Menzies, A., Tsang, V., Long, G., Tonks, K. (2018). Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. Pituitary, 21(3), 274-282. [More Information]
Gild, M., Tsang, V., Samra, J., Clifton-Bligh, R., Tacon, L., Gill, A. (2018). Hypercalcemia in glucagon cell hyperplasia and neoplasia (Mahvash syndrome): a new association. Journal of Clinical Endocrinology and Metabolism, 103(9), 3119-3123. [More Information]
Jang, H., Parratt, J., Tsang, V., Coyle, L., Fernando, S. (2018). Serum vascular endothelial growth factor (VEGF) level can be used as a diagnostic marker in POEMS syndrome. Pathology, 50(6), 674-676. [More Information]
Scott, E., Long, G., Guminski, A., Clifton-Bligh, R., Menzies, A., Tsang, V. (2018). The Spectrum, Incidence, Kinetics, and Management of Endocrinopathies with Immune Checkpoint Inhibitors for Metastatic Melanoma. European Journal of Endocrinology, 178(2), 175-182. [More Information]

show 1 more

2017

Wijewardene, A., Glastras, S., Learoyd, D., Robinson, B., Tsang, V. (2017). ACTH-secreting medullary thyroid cancer: a case series. Endocrinology, Diabetes & Metabolism Case Reports, 2017, 1-6. [More Information]
Kam, J., Tsang, V., Chalasani, V. (2017). Retrograde Ejaculation: A Rare Presenting Symptom of Type 1 Diabetes Mellitus. Urology Case Reports, 10, 9-10. [More Information]

2016

Logaraj, A., Tsang, V., Kabir, S., Ip, J. (2016). Adrenal crisis secondary to bilateral adrenal haemorrhage after hemicolectomy. Endocrinology, Diabetes & Metabolism Case Reports, 2016, 1-4. [More Information]
Fraser, S., Go, C., Aniss, A., Sidhu, S., Delbridge, L., Learoyd, D., Clifton-Bligh, R., Tacon, L., Tsang, V., Robinson, B., Gill, A., Sywak, M. (2016). BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer. World Journal of Surgery, 40(7), 1618-1624. [More Information]
Tsang, V., Robinson, B., Learoyd, D. (2016). The safety of vandetanib for the treatment of thyroid cancer. Expert Opinion on Drug Safety, 15(8), 1107-1113. [More Information]

2015

Kozusko, K., Tsang, V., Bottomley, W., Cho, Y., Gandotra, S., Mimmack, M., Lim, K., Isaac, I., Patel, S., Saudek, V., et al (2015). Clinical and molecular characterization of a novel PLIN1 frameshift mutation identified in patients with familial partial lipodystrophy. Diabetes, 64(1), 299-310. [More Information]
Tsang, V., Tacon, L., Learoyd, D., Robinson, B. (2015). Pheochromocytomas in Multiple Endocrine Neoplasia Type 2. In Friedhelm Raue (Eds.), Medullary Thyroid Carcinoma: Biology - Management - Treatment, (pp. 157-178). Cham: Springer. [More Information]
Kim, E., Rath, E., Tsang, V., Duff, A., Robinson, B., Church, W., Benn, D., Dwight, T., Clifton-Bligh, R. (2015). Structural and functional consequences of succinate dehydrogenase subunit B mutations. Endocrine-Related Cancer, 22(3), 387-397. [More Information]

2014

Tsang, V., Dwight, T., Benn, D., Meyer-Rochow, G., Gill, A., Sywak, M., Sidhu, S., Veivers, D., Sue, C., Robinson, B., Clifton-Bligh, R., Parker, N. (2014). Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours. Endocrine-Related Cancer, 21(3), 415-426. [More Information]

2012

Tsang, V., Parker, N., Cassano, J., Dwight, T., Sue, C., Veivers, D., Robinson, B., Benn, D., Clifton-Bligh, R. (2012). Interaction between hypoxia and mutations in the SDH subunit genes associated with phaeochromocytoma/paragangliomas. 2012 Annual Scientific Meeting of the Endocrine Society of Australia and the Society for Reproductive Biology, Gold Coast, Queensland, Australia.

2011

Tsang, V., Benn, D., Gill, A., Sywak, M., Sidhu, S., Robinson, B., Clifton-Bligh, R., Parker, N. (2011). MiR210 is elevated in SDHB-mutated phaeochromocytoma and paragangliomas (poster). 3rd International Symposium on Pheochromocytoma and Paraganglioma, Paris, France.

2010

Tsang, V., Campbell, L. (2010). Catecho-Strophic Diabetic Ketoacidosis. The Best of Grand Rounds Wiley-Blackwell Publishing Award for Clinical Excellence. Internal Medicine Journal, 40(Suppl. 1), 58-58. [More Information]

Faculty of Medicine and Health

Page not found

Associate Professor Venessa Hin Man Tsang

Publications

By Type

By Year